91 related articles for article (PubMed ID: 29527921)
1. A blood pact: the significance and implications of eIF4E on lymphocytic leukemia.
Venturi V; Masek T; Pospisek M
Physiol Res; 2018 Jul; 67(3):363-382. PubMed ID: 29527921
[TBL] [Abstract][Full Text] [Related]
2. Eukaryotic translation initiation factor 4E as a novel therapeutic target in hematological malignancies and beyond.
Pettersson F; Del Rincon SV; Miller WH
Expert Opin Ther Targets; 2014 Sep; 18(9):1035-48. PubMed ID: 25004955
[TBL] [Abstract][Full Text] [Related]
3. Ribavirin Inhibits the Activity of mTOR/eIF4E, ERK/Mnk1/eIF4E Signaling Pathway and Synergizes with Tyrosine Kinase Inhibitor Imatinib to Impair Bcr-Abl Mediated Proliferation and Apoptosis in Ph+ Leukemia.
Shi F; Len Y; Gong Y; Shi R; Yang X; Naren D; Yan T
PLoS One; 2015; 10(8):e0136746. PubMed ID: 26317515
[TBL] [Abstract][Full Text] [Related]
4. Signalling to eIF4E in cancer.
Siddiqui N; Sonenberg N
Biochem Soc Trans; 2015 Oct; 43(5):763-72. PubMed ID: 26517881
[TBL] [Abstract][Full Text] [Related]
5. The eukaryotic translation initiation factor eIF4E in the nucleus: taking the road less traveled.
Osborne MJ; Borden KL
Immunol Rev; 2015 Jan; 263(1):210-23. PubMed ID: 25510279
[TBL] [Abstract][Full Text] [Related]
6. Dual targeting of eIF4E by blocking MNK and mTOR pathways in leukemia.
Kosciuczuk EM; Saleiro D; Platanias LC
Cytokine; 2017 Jan; 89():116-121. PubMed ID: 27094611
[TBL] [Abstract][Full Text] [Related]
7. Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin.
Assouline S; Culjkovic B; Cocolakis E; Rousseau C; Beslu N; Amri A; Caplan S; Leber B; Roy DC; Miller WH; Borden KL
Blood; 2009 Jul; 114(2):257-60. PubMed ID: 19433856
[TBL] [Abstract][Full Text] [Related]
8. The eukaryotic translation initiation factor eIF4E is a direct transcriptional target of NF-κB and is aberrantly regulated in acute myeloid leukemia.
Hariri F; Arguello M; Volpon L; Culjkovic-Kraljacic B; Nielsen TH; Hiscott J; Mann KK; Borden KL
Leukemia; 2013 Oct; 27(10):2047-55. PubMed ID: 23467026
[TBL] [Abstract][Full Text] [Related]
9. [Expression of eIF4E in patients with leukemia and its clinical significance].
Zhu LF; Chen XJ; Hu JD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb; 21(1):1-6. PubMed ID: 23484680
[TBL] [Abstract][Full Text] [Related]
10. The antileukemia roles of PP242 alone or in combination with daunorubicin in acute leukemia.
Shi F; Yang X; Gong Y; Shi R; Yang X; Naren D; Wu J
Anticancer Drugs; 2015 Apr; 26(4):410-21. PubMed ID: 25535978
[TBL] [Abstract][Full Text] [Related]
11. Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G.
Moerke NJ; Aktas H; Chen H; Cantel S; Reibarkh MY; Fahmy A; Gross JD; Degterev A; Yuan J; Chorev M; Halperin JA; Wagner G
Cell; 2007 Jan; 128(2):257-67. PubMed ID: 17254965
[TBL] [Abstract][Full Text] [Related]
12. Eukaryotic translation initiation factor 4E activity is modulated by HOXA9 at multiple levels.
Topisirovic I; Kentsis A; Perez JM; Guzman ML; Jordan CT; Borden KL
Mol Cell Biol; 2005 Feb; 25(3):1100-12. PubMed ID: 15657436
[TBL] [Abstract][Full Text] [Related]
13. Expression of the eukaryotic translation initiation factor 4E (eIF4E) and 4E-BP1 in esophageal cancer.
Salehi Z; Mashayekhi F
Clin Biochem; 2006 Apr; 39(4):404-9. PubMed ID: 16375881
[TBL] [Abstract][Full Text] [Related]
14. Sodium arsenite-induced inhibition of eukaryotic translation initiation factor 4E (eIF4E) results in cytotoxicity and cell death.
Othumpangat S; Kashon M; Joseph P
Mol Cell Biochem; 2005 Nov; 279(1-2):123-31. PubMed ID: 16283521
[TBL] [Abstract][Full Text] [Related]
15. eIF4E/4E-BP ratio predicts the efficacy of mTOR targeted therapies.
Alain T; Morita M; Fonseca BD; Yanagiya A; Siddiqui N; Bhat M; Zammit D; Marcus V; Metrakos P; Voyer LA; Gandin V; Liu Y; Topisirovic I; Sonenberg N
Cancer Res; 2012 Dec; 72(24):6468-76. PubMed ID: 23100465
[TBL] [Abstract][Full Text] [Related]
16. Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia.
Urtishak KA; Wang LS; Culjkovic-Kraljacic B; Davenport JW; Porazzi P; Vincent TL; Teachey DT; Tasian SK; Moore JS; Seif AE; Jin S; Barrett JS; Robinson BW; Chen IL; Harvey RC; Carroll MP; Carroll AJ; Heerema NA; Devidas M; Dreyer ZE; Hilden JM; Hunger SP; Willman CL; Borden KLB; Felix CA
Oncogene; 2019 Mar; 38(13):2241-2262. PubMed ID: 30478448
[TBL] [Abstract][Full Text] [Related]
17. The emerging roles of translation factor eIF4E in the nucleus.
Strudwick S; Borden KL
Differentiation; 2002 Mar; 70(1):10-22. PubMed ID: 11963652
[TBL] [Abstract][Full Text] [Related]
18. The Structures of eIF4E-eIF4G Complexes Reveal an Extended Interface to Regulate Translation Initiation.
Grüner S; Peter D; Weber R; Wohlbold L; Chung MY; Weichenrieder O; Valkov E; Igreja C; Izaurralde E
Mol Cell; 2016 Nov; 64(3):467-479. PubMed ID: 27773676
[TBL] [Abstract][Full Text] [Related]
19. Eukaryotic translation initiation is controlled by cooperativity effects within ternary complexes of 4E-BP1, eIF4E, and the mRNA 5' cap.
Modrak-Wojcik A; Gorka M; Niedzwiecka K; Zdanowski K; Zuberek J; Niedzwiecka A; Stolarski R
FEBS Lett; 2013 Dec; 587(24):3928-34. PubMed ID: 24211447
[TBL] [Abstract][Full Text] [Related]
20. Phosphorylation of eIF4E Confers Resistance to Cellular Stress and DNA-Damaging Agents through an Interaction with 4E-T: A Rationale for Novel Therapeutic Approaches.
Martínez A; Sesé M; Losa JH; Robichaud N; Sonenberg N; Aasen T; Ramón Y Cajal S
PLoS One; 2015; 10(4):e0123352. PubMed ID: 25923732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
